GROUPE CANADIEN D'APHÉRÈSE
CANADIAN APHERESIS GROUP
Update on Clinical Trials and Activities: January 2011
Voluven® In Europe, Fresenius Kabi has introduced Voluven® 6% (hydroxyethylstarch) solution for infusion, as a blood volume expander. The company says that Voluven® has the same volume expansion effect as its HAES-Steril intravenous infusion, but has a lower molecular weight, a lower degree of substitution on the molecule and fewer side effects. Dr. David Barth has just completed an assessment in Toronto.
Octaplas Octaplas (a product manufactured by Octapharma in Vienna) is a frozen plasma product which has been licensed for use in Canada for many years. Octaplas possesses much the same clinical activity as normal human FFP. After Solvent Detergent (SD) treatment and subsequent removal of the SD reagents, the plasma protein content in Octaplas remains at comparable levels to those in FFP, i.e. 45-70 mg/ml. The coagulation activity values are close to the corresponding values for normal human FFP and a minimum of 0.5 IU/ml is obtained for each coagulation factor. The finished product is tested for coagulation factors V, VIII, XI. However, as a result of the SD treatment and purification, the content of lipids and lipoproteins is reduced. The shelf-life of Octaplas is two years when stored at < -30oC and protected from light. Once the bag has been opened, the product must be used immediately, within one hour after thawing. The CAG has formally requested CBS to have the product available for use in Canada for our TTP patients.
Voluven® In Europe, Fresenius Kabi has introduced Voluven® 6% (hydroxyethylstarch) solution for infusion, as a blood volume expander. The company says that Voluven® has the same volume expansion effect as its HAES-Steril intravenous infusion, but has a lower molecular weight, a lower degree of substitution on the molecule and fewer side effects. Dr. David Barth has just completed an assessment in Toronto.
Octaplas Octaplas (a product manufactured by Octapharma in Vienna) is a frozen plasma product which has been licensed for use in Canada for many years. Octaplas possesses much the same clinical activity as normal human FFP. After Solvent Detergent (SD) treatment and subsequent removal of the SD reagents, the plasma protein content in Octaplas remains at comparable levels to those in FFP, i.e. 45-70 mg/ml. The coagulation activity values are close to the corresponding values for normal human FFP and a minimum of 0.5 IU/ml is obtained for each coagulation factor. The finished product is tested for coagulation factors V, VIII, XI. However, as a result of the SD treatment and purification, the content of lipids and lipoproteins is reduced. The shelf-life of Octaplas is two years when stored at < -30oC and protected from light. Once the bag has been opened, the product must be used immediately, within one hour after thawing. The CAG has formally requested CBS to have the product available for use in Canada for our TTP patients.
Copyright © 2005-2011 Canadian Apheresis Group
Representing Apheresis Practitioners in Canada
Site Sponsor
and
TERUMO TRANSFUSION are becoming TERUMOBCT
TERUMO TRANSFUSION are becoming TERUMOBCT